TY - JOUR
T1 - Prevalence and Risk of Metastatic Thyroid Cancers and Management Outcomes
T2 - A National Perspective
AU - Al-Qurayshi, Zaid
AU - Sullivan, Christopher B.
AU - Pagedar, Nitin
AU - Lee, Grace S.
AU - Tufano, Ralph
AU - Kandil, Emad
N1 - Funding Information:
This study was supported by the National Institutes of Health (NIH)–Institutional National Research Award, T32 #5T32DC000040 ( z.a‐q .). The authors have no other funding, financial relationships, or conflicts of interest to disclose.
Publisher Copyright:
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.
PY - 2021/1
Y1 - 2021/1
N2 - Objectives: Examine the prevalence and risk of metastasis in thyroid cancers and management outcomes. Study design: Retrospective analysis of the National Cancer Database, 2004–2014. Methods: The study population included adult (≥ 18 years) patients with thyroid cancer. Analysis included multivariate logistic regression and Cox hazard ratio modeling. Results: A total of 152,979 patients were included. Distant metastasis was reported in 1,867 (1.22%) patients. The distribution of metastatic cases based on pathology and tumor size were as follows in descending order: papillary thyroid carcinoma (PTC) 1 to 4 cm (30.53%), PTC > 4 cm (19.34%), undifferentiated (UTC) > 4 cm (14.14%), PTC < 1 cm (8.46%), follicular thyroid carcinoma (FTC) > 4 cm (7.28%), FTC 1 to 4 cm (5.52%), medullary thyroid cancer (MTC) ≤ 4 cm (3.96%), MTC > 4 cm (3.91%), UTC ≤ 4 cm (3.32%), Hürthle (HCC) > 4 cm (2.09%), and HCC 1 to 4 cm (1.45%). Significant predictors of distant metastasis, while controlling for tumor pathology and size, included older age, male gender, non-White minorities, presence of multiple comorbidities, minimal, gross extrathyroidal extension (ETE), lymphovascular invasion (LVI), and concomitant central and lateral lymph node metastasis (LNM) (P <.05 each). The risk of distant metastasis in the absence of nodal metastasis, ETE, and LVI was highest for FTC > 4 cm. Conclusion: Although the risk of metastasis in well-differentiated thyroid carcinoma (WDTC) is low, the prevalence of metastatic thyroid cancer is highest in WDTC population because it is the most common type of thyroid cancer. Certain pathological features, including minimal ETE and central LNM, are associated with a higher prevalence of metastatic disease. Level of Evidence: NA Laryngoscope, 131:237–244, 2021.
AB - Objectives: Examine the prevalence and risk of metastasis in thyroid cancers and management outcomes. Study design: Retrospective analysis of the National Cancer Database, 2004–2014. Methods: The study population included adult (≥ 18 years) patients with thyroid cancer. Analysis included multivariate logistic regression and Cox hazard ratio modeling. Results: A total of 152,979 patients were included. Distant metastasis was reported in 1,867 (1.22%) patients. The distribution of metastatic cases based on pathology and tumor size were as follows in descending order: papillary thyroid carcinoma (PTC) 1 to 4 cm (30.53%), PTC > 4 cm (19.34%), undifferentiated (UTC) > 4 cm (14.14%), PTC < 1 cm (8.46%), follicular thyroid carcinoma (FTC) > 4 cm (7.28%), FTC 1 to 4 cm (5.52%), medullary thyroid cancer (MTC) ≤ 4 cm (3.96%), MTC > 4 cm (3.91%), UTC ≤ 4 cm (3.32%), Hürthle (HCC) > 4 cm (2.09%), and HCC 1 to 4 cm (1.45%). Significant predictors of distant metastasis, while controlling for tumor pathology and size, included older age, male gender, non-White minorities, presence of multiple comorbidities, minimal, gross extrathyroidal extension (ETE), lymphovascular invasion (LVI), and concomitant central and lateral lymph node metastasis (LNM) (P <.05 each). The risk of distant metastasis in the absence of nodal metastasis, ETE, and LVI was highest for FTC > 4 cm. Conclusion: Although the risk of metastasis in well-differentiated thyroid carcinoma (WDTC) is low, the prevalence of metastatic thyroid cancer is highest in WDTC population because it is the most common type of thyroid cancer. Certain pathological features, including minimal ETE and central LNM, are associated with a higher prevalence of metastatic disease. Level of Evidence: NA Laryngoscope, 131:237–244, 2021.
KW - Thyroid cancer
KW - distant metastasis
KW - radiotherapy
KW - thyroid surgery
KW - tumor size
UR - http://www.scopus.com/inward/record.url?scp=85087173064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087173064&partnerID=8YFLogxK
U2 - 10.1002/lary.28722
DO - 10.1002/lary.28722
M3 - Article
C2 - 32574405
AN - SCOPUS:85087173064
SN - 0023-852X
VL - 131
SP - 237
EP - 244
JO - Laryngoscope
JF - Laryngoscope
IS - 1
ER -